Exenatide in acute ischemic stroke

International Journal of Stroke

Volumn 8, Issue 7, 2013, Pages

  Daly, Samantha C ^a   Chemmanam, Thomas ^a   Loh, Poh Sien ^a   Gilligan, Amanda ^a   Dear, Anthony E ^a   Simpson, Richard W ^a   Bladin, Christopher F ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; EXENDIN 4;

BRAIN ISCHEMIA; DEATH; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LENGTH OF STAY; LETTER; NAUSEA; PRIORITY JOURNAL; RANKIN SCALE; SIDE EFFECT; VOMITING;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PEPTIDES; PILOT PROJECTS; STROKE; VENOMS;

EID: 84884314832     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12073     Document Type: Letter

References (3)

1. Gray CS, Hildreth AJ, Sandercock PA etal. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6:397-406.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705.
3. Teramoto S, Miyamoto N, Yatomi K etal. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011; 31:1696-1705.